Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Operating Leases (2019 - 2025)

Puma Biotechnology (PBYI) has disclosed Operating Leases for 7 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 215.19% year-over-year to $4.7 million, compared with a TTM value of $4.7 million through Dec 2025, up 215.19%, and an annual FY2025 reading of $4.7 million, up 215.19% over the prior year.
  • Operating Leases was $4.7 million for Q4 2025 at Puma Biotechnology, down from $7.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $18.7 million in Q1 2021 and bottomed at $1.5 million in Q4 2024.
  • Average Operating Leases over 5 years is $10.7 million, with a median of $11.3 million recorded in 2022.
  • The sharpest move saw Operating Leases tumbled 78.76% in 2024, then skyrocketed 215.19% in 2025.
  • Year by year, Operating Leases stood at $16.0 million in 2021, then decreased by 25.92% to $11.8 million in 2022, then crashed by 40.56% to $7.0 million in 2023, then crashed by 78.76% to $1.5 million in 2024, then surged by 215.19% to $4.7 million in 2025.
  • Business Quant data shows Operating Leases for PBYI at $4.7 million in Q4 2025, $7.3 million in Q3 2025, and $4.4 million in Q2 2025.